Lithium and suicide prevention in mood disorders and in the general population: A systematic review

  title={Lithium and suicide prevention in mood disorders and in the general population: A systematic review},
  author={L. Del Matto and Michele Muscas and Andrea Murru and Norma Verdolini and Gerard Anmella and Giovanna Fico and Filippo Corponi and Andr{\'e} Ferrer Carvalho and Ludovic Samalin and Bernardo Carpiniello and Andrea Fagiolini and Eduard Vieta and Isabella Pacchiarotti},
  journal={Neuroscience \& Biobehavioral Reviews},
Suicide prevention in psychiatric patients
Developing of suicide prevention in psychiatric patients will require a better understanding of additional risk and protective factors, such as the role of a person's decision‐making capacity and social support, the roles of spiritual and religious interventions, and the reduction of the treatment gap in mental health care.
Lithium in Drinking Water as a Public Policy for Suicide Prevention: Relevance and Considerations
Although suicide is considered a major preventable cause of mortality worldwide, we do not have effective strategies to prevent it. Lithium has been consistently associated with lowering risk of
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review.
This work sought to identify scalable evidence-based suicide prevention strategies by evaluating newer approaches, such as electronic health record-derived algorithms, Internet-based screening methods, ketamine's potential benefit for preventing attempts, and passive monitoring of acute suicide risk change.
The clean and dirty ways to reduce suicidality
Clozapine and lithium have an outstanding ability to reduce the probability of suicide, and their common property, which determines (along with other pharmacological effects) their antisuicidal potential, is the reduction of impulsivity and aggression.
Life expectancy and years of potential life lost in bipolar disorder: systematic review and meta-analysis.
Bipolar disorder is associated with substantially shortened life expectancy and implementation of multilevel, targeted interventions is urgently needed to reduce this mortality gap.
Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001–2017
Assessment of real-life utilization of psychotropic drugs based on severity of MDD in psychiatric inpatients reveals substantial discrepancies between guideline recommendations and real- life drug utilization, indicating that guidelines may insufficiently consider clinical needs within the psychiatric inpatient setting.


Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Lithium is an effective treatment for reducing the risk of suicide in people with mood disorders and may exert its antisuicidal effects by reducing relapse of mood disorder.
Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide.
The results suggest that treatment with lithium may have some superiority in relation to prevention of suicide in patients discharged nationwide from hospital psychiatry with a diagnosis of bipolar disorder.
Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review.
Risks of completed and attempted suicide were consistently lower, by approximately 80%, during treatment of bipolar and other major affective disorder patients with lithium for an average of 18 months, and these benefits were sustained in randomized as well as open clinical trials.
Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior.
Despite the high frequency of suicide events during the study, this randomized controlled trial detected no difference between lithium and valproate in time to suicide attempt or suicide event in a sample of suicide attempters with bipolar disorder.
Antisuicidal Effects in Mood Disorders: Are They Unique to Lithium?
Substantial reduction of risks of suicide and attempts with long-term lithium treatment, particularly in depressive phases of BD and in MDD, and in mixed (agitated-dysphoric) states than in manic or hypomanic periods.
Suicide risk in bipolar disorder during treatment with lithium and divalproex.
Among patients treated for bipolar disorder, risk of suicide attempt and suicide death is lower during treatment with lithium than duringreatment with divalproex, according to a retrospective cohort study conducted at 2 large integrated health plans in California and Washington.
Suicide in 406 Mood-Disorder Patients With and Without Long-Term Medication: A 40 to 44 Years' Follow-Up
ABSTRACT There is no data on the variation in the suicide risk over lifetime and on the suicide-preventive effect of the long-term treatment of mood-disorder patients with antidepressants and
Heterogeneity of the risk of suicidal behavior in bipolar-spectrum disorders.
Suicidal behavior is distributed unevenly in families of probands with BD, aggregating in a subset of families and the results suggest that partially overlapping sets of genetic factors may underlie BD and suicide.
Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders.
Lithium maintenance is associated with sustained reduction of suicidal acts in manic-depressive disorders and improved diagnosis and treatment as well as earlier intervention for potentially lethal bipolar depression are urgently needed.
Understanding suicide: Focusing on its mechanisms through a lithium lens.